Sanofi confirms 2020 outlook – Short term recovery is ongoing
Nicolas Suiffet April 24, 2020 8:55 AM
Sanofi, a pharmaceutical group, announced that 1Q business net income rose 15.9% on year to 2.04 billion euros and business operating income increased 15.8% to 2.66 billion euros on net sales of 8.97 billion euros, up 6.9%
Sanofi, a pharmaceutical group, announced that 1Q business net income rose 15.9% on year to 2.04 billion euros and business operating income increased 15.8% to 2.66 billion euros on net sales of 8.97 billion euros, up 6.9% (+6.6% at constant exchange rates). The company said it continues to expect business EPS to grow around 5% at constant exchange rates (+15.6% in 1Q).
Global healthcare stocks have recently outperformed the STOXX 600 in Europe. From a technical point of view, Sanofi remains in a short term bullish trend, within a bullish channel. The daily Relative Strength Index (RSI, 14) is bullish and not overbought. The stock price is trading above its 50DMA which started to flatten out. This may indicate an imminent consolidation move for the stock as prices are approaching from Feb 19th high at 95E.
Immediate support is set 86.6E near the 100DMA but the key short term support threshold is set at 80.7E. A break above 95E would open the way to a further rise towards 99E (upper Bollinger boundary on a weekly chart).
Source: GAIN Capital, TradingView
StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.